Obalon Therapeutics Inc is categorized under Commercial Photo Laboratories in Carlsbad, CA and active since 2008.
Obalon Therapeutics Inc was established in 2008, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Photo Laboratories business, which does work in the B2B market, and is classified as a Commercial Photo Laboratories, under code number 812921 by the NAICS.
If you are seeking more information, feel free to contact Andrew P Rasdal at the company’s headquarters by writing to 5421 Avd Encinas # F, Carlsbad, California CA 92008 or by phoning (760) 607-5151. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Obalon Therapeutics Inc |
| Contact Person: | Andrew P Rasdal |
| Address: | 5421 Avd Encinas # F, Carlsbad, California 92008 |
| Phone Number: | (760) 607-5151 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2008 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Photo Laboratories |
| SIC Code: | 7384 |
| NAICS Code: | 812921 |
| Share This Business: |
Obalon Therapeutics Inc was started in 2008 to provide professional Commercial Photo Laboratories under the SIC code 7384 and NAICS code 812921. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Andrew P Rasdal for inquiries that concern Obalon Therapeutics Inc by calling the company number (760) 607-5151, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Obalon Therapeutics Inc can be found at the coordinates 33.128473,-117.326537 as well as the street address 5421 Avd Encinas # F in Carlsbad, California 92008.
For its online presence, you may visit Obalon Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.